Request Trial
23 October 2017Americas

Generic Restasis plans revealed days after patent invalidation

A San Diego-based company has announced plans to sell a generic version of Allergan’s dry eye disease treatment Restasis (cyclosporine ophthalmic emulsion), just days after four patents covering the drug were invalidated.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Why the US is poised for a patent litigation surge in 2026
12 January 2026   After “seismic” changes imposed by the USPTO last year, litigating patents will become significantly more difficult and costly to defend, and both plaintiffs and defendants must urgently retool their strategies, advise lawyers from BCLP.
Americas
From migraine drugs to COVID vaccine spats, US lawsuits pile up
9 January 2026   A busy week in US courts saw major pharma companies and biotech firms move to protect key therapies and research tools, with new lawsuits over migraine and cancer drug generics, and alleged misuse of COVID-19 vaccine tech.
Americas
Insulin pump rivals face off in major trade secrets dispute hearing
8 January 2026   Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.


Editor's picks

Deadline extended: Who are the world’s best in-house counsel?
Europe
Deadline extended: Who are the world’s best in-house counsel?
9 January 2026

Editor's picks

Europe
Deadline extended: Who are the world’s best in-house counsel?
9 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025
Europe
Abbott appeals ‘baffling’ decision in glucose monitoring device feud
16 December 2025
Americas
Teva scrubs 200-plus Orange Book patents after FTC turns the screw
11 December 2025
Americas
US govt backs Hikma over ‘skinny label’ rules
9 December 2025
Big Pharma
The clinical trial dilemma: Navigating European practice
27 November 2025

More features

Carpmaels & Ransford builds Munich UPC team with elite hire
Why the US is poised for a patent litigation surge in 2026
From migraine drugs to COVID vaccine spats, US lawsuits pile up
How AI will be shaped by legal and regulatory developments in 2026
Deadline extended: Who are the world’s best in-house counsel?
‘All voices must be heard’: New CIPA president sets out plans for 2026
Insulin pump rivals face off in major trade secrets dispute hearing
Bayer enters COVID-19 vaccine row with three suits against major drugmakers